Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use
Objective: To evaluate the results obtained with the combined use of nab-paclitaxel and gemcitabine in the treatment of patients with metastatic pancreatic adenocarcinoma. Materials and methods: Retrospective observational study. Patients treated with nab-paclitaxel and gemcitabine between January...
Main Authors: | Elena Ferris Villanueva, Mónica Martínez Penella, Pablo Cerezuela Fuentes, Rocío Guerrero Bautista, Andrés García Márquez, María Del Carmen Mira Sirvent |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2015-02-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/8517.pdf |
Similar Items
-
Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
by: Zong Y, et al.
Published: (2020-12-01) -
Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
by: Jane E. Rogers, et al.
Published: (2020-08-01) -
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
by: Ursula M. Vogl, et al.
Published: (2019-01-01) -
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Sara Pusceddu, et al.
Published: (2019-04-01) -
Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
by: I. A. Pokataev, et al.
Published: (2019-12-01)